Comparing Fetoscopic Surgery Protocols

NCT ID: NCT05654064

Last Updated: 2022-12-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

NA

Study Classification

INTERVENTIONAL

Study Start Date

2022-04-30

Study Completion Date

2024-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Determine surgeon and patient satisfaction with remifentanil-dexmedetomidine (REMI) and dexmedetomidine-fentanyl (DEX) sedation protocols in pregnant patients undergoing minimally invasive fetoscopic procedures

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Minimally Invasive Fetoscopic Procedures

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

DOUBLE

Participants Caregivers
Participant and surgeon will be blinded to which combination of medications are used during the procedure.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Remifentanil-dexmedetomidine

Group Type ACTIVE_COMPARATOR

Remifentanil-dexmedetomidine

Intervention Type DRUG

Compare adequacy of remifentanil-dexmedetomidine sedation protocols in pregnant patients undergoing minimally invasive fetoscopic procedures.

Dexmedetomidine- fentanyl

Group Type ACTIVE_COMPARATOR

Dexmedetomidine-fentanyl

Intervention Type DRUG

Compare adequacy of dexmedetomidine-fentanyl sedation protocols in pregnant patients undergoing minimally invasive fetoscopic procedures.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Remifentanil-dexmedetomidine

Compare adequacy of remifentanil-dexmedetomidine sedation protocols in pregnant patients undergoing minimally invasive fetoscopic procedures.

Intervention Type DRUG

Dexmedetomidine-fentanyl

Compare adequacy of dexmedetomidine-fentanyl sedation protocols in pregnant patients undergoing minimally invasive fetoscopic procedures.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Pregnant patients undergoing one of the following procedures

* Laser photocoagulation of abnormal anastomotic vessels in patients with a twin-twin transfusion syndrome
* Selective radiofrequency ablation or fetoscopic cord coagulation in patients with TRAP sequence or in the presence of intrauterine death of one twin
* Vesicoamniotic shunts or placement of amnioports in patients with LUTO
* Placement of amnioports in patients with oligohydramnios or anhydramnios
* Fetal thoracentesis or placement of thoracoamniotic shunts in patients with congenital pulmonary airway malformation or fetal hydrothorax
* FETO (fetoscopic endotracheal occlusion) as well as balloon removal in patients with congenital diaphragmatic hernia and laser release of amniotic bands

Exclusion Criteria

Pregnant patients undergoing fetoscopic procedures requiring the following

* Additional procedures (e.g. cerclage)
* Laparotomy with uterine exteriorization to access the uterine cavity
* General anesthesia
* Mid-gestation neural tube defect repair
* EXIT procedures
* Preoperative opioid use
* Diagnosed substance abuse
* Moderate to severe obstructive sleep apnea
* History of allergic reactions to medications to be administered during the study
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Children's Hospital Medical Center, Cincinnati

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mario Patino, MD

Role: PRINCIPAL_INVESTIGATOR

Children's Hospital Medical Center, Cincinnati

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2022-0168

Identifier Type: -

Identifier Source: org_study_id